Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY

(MRK)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Merck and : Gets Positive EU CHMP Opinion for Two New Regimens of Keytruda

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/18/2019 | 07:36am EST

By Michael Dabaie

Merck & Co. (MRK) said the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended approval of two regimens of Keytruda for the first-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma.

Keytruda, as monotherapy or in combination with platinum and 5-fluorouracil chemotherapy, is recommended in patients whose tumors express PD-L1, said the Kenilworth, N.J., company, which is known as MSD outside the U.S. and Canada.

The CHMP recommendation is based on data from the pivotal Phase 3 KEYNOTE-048 trial, in which Keytruda demonstrated a significant improvement in overall survival, compared with standard treatment.

The European Commission for marketing authorization in the EU will now review the CHMP's recommendation and a final decision is expected in the fourth quarter of 2019, Merck said.

Write to Michael Dabaie at michael.dabaie@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK AND COMPANY
11/15MERCK AND : AstraZeneca - US FDA accepts regulatory submission for selumetinib i..
AQ
11/15MERCK AND : Gets FDA OK for Bravecto Plus Topical Solution for Cats
DJ
11/15MERCK AND : BRAVECTO® PLUS (fluralaner and moxidectin topical solution) for Cats..
BU
11/14MERCK AND : ERVEBO® Awarded Prequalification Status by the World Health Organiza..
AQ
11/14Walt Disney soars while Cisco disappoints
11/14MERCK AND : ERVEBO® Awarded Prequalification Status by the World Health Organiza..
AQ
11/14Merck, AstraZeneca Get FDA Priority Review for Selumetinib in NF1
DJ
11/14MERCK AND : US FDA Accepts Regulatory Submission of New Drug Application for Sel..
BU
11/14MERCK AND : US FDA accepts regulatory submission for selumetinib in neurofibroma..
AQ
11/12Wall Street in full speed
More news
Financials (USD)
Sales 2019 46 560 M
EBIT 2019 16 323 M
Net income 2019 10 062 M
Debt 2019 20 850 M
Yield 2019 2,62%
P/E ratio 2019 21,9x
P/E ratio 2020 17,0x
EV / Sales2019 5,09x
EV / Sales2020 4,75x
Capitalization 216 B
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 18
Average target price 97,65  $
Last Close Price 84,90  $
Spread / Highest target 23,7%
Spread / Average Target 15,0%
Spread / Lowest Target 6,01%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Sandy Tremps Vice President-R&D IT CIO
James H. Scholefield Chief Information & Digital Officer
Thomas Henry Glocer Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY11.11%216 154
JOHNSON & JOHNSON1.48%355 145
ROCHE HOLDING AG20.79%255 382
PFIZER-14.59%206 312
NOVARTIS18.75%202 726
NOVO NORDISK AS30.56%135 921